|
1
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar
|
|
2
|
Oettle H, Post S, Neuhaus P, et al:
Adjuvant chemotherapy with gemcitabine vs observation in patients
undergoing curative-intent resection of pancreatic cancer: a
randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar
|
|
3
|
Diaz-Rubio E: New chemotherapeutic
advances in pancreatic, colorectal, and gastric cancers.
Oncologist. 9:282–294. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shaw VE, Naisbitt DJ, Costello E, et al:
Current status of GV1001 and other telomerase vaccination
strategies in the treatment of cancer. Expert Rev Vaccines.
9:1007–1016. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nowak AK, Lake RA, Marzo AL, et al:
Induction of tumor cell apoptosis in vivo increases tumor antigen
cross-presentation, cross-priming rather than cross-tolerizing host
tumor-specific CD8 T cells. J Immunol. 170:4905–4913. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Correale P, Cusi MG, Tsang KY, et al:
Chemo-immunotherapy of metastatic colorectal carcinoma with
gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte
macrophage colony-stimulating factor and interleukin-2 induces
strong immunologic and antitumor activity in metastatic colon
cancer patients. J Clin Oncol. 23:8950–8958. 2005.
|
|
7
|
Tseng JF, Willett CG, Fernandez-del
Castillo C, et al: Patients undergoing treatment for pancreatic
adenocarcinoma can mount an effective immune response to
vaccinations. Pancreatology. 5:67–74. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Plate JM, Plate AE, Shott S, Bograd S and
Harris JE: Effect of gemcitabine on immune cells in subjects with
adenocarcinoma of the pancreas. Cancer Immunol Immunother.
54:915–925. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hiyama E, Kodama T, Shinbara K, et al:
Telomerase activity is detected in pancreatic cancer but not in
benign tumors. Cancer Res. 57:326–331. 1997.PubMed/NCBI
|
|
10
|
Kyte JA, Gaudernack G, Dueland S, Trachsel
S, Julsrud L and Aamdal S: Telomerase peptide vaccination combined
with temozolomide: a clinical trial in stage IV melanoma patients.
Clin Cancer Res. 17:4568–4580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brunsvig PF, Aamdal S, Gjertsen MK, et al:
Telomerase peptide vaccination: a phase I/II study in patients with
non-small cell lung cancer. Cancer Immunol Immunother.
55:1553–1564. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bernhardt SL, Gjertsen MK, Trachsel S, et
al: Telomerase peptide vaccination of patients with non-resectable
pancreatic cancer: A dose escalating phase I/II study. Br J Cancer.
95:1474–1482. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Almoguera C, Shibata D, Forrester K,
Martin J, Arnheim N and Perucho M: Most human carcinomas of the
exocrine pancreas contain mutant c-K-ras genes. Cell. 53:549–554.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ullenhag GJ, Frodin JE, Mosolits S, et al:
Immunization of colorectal carcinoma patients with a recombinant
canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA)
and granulocyte macrophage colony- stimulating factor induced a
tumor-specific cellular immune response. Clin Cancer Res.
9:2447–2456. 2003.
|
|
15
|
Mosolits S, Markovic K, Frodin JE, et al:
Vaccination with Ep-CAM protein or anti-idiotypic antibody induces
Th1-biased response against MHC class I- and II-restricted Ep-CAM
epitopes in colorectal carcinoma patients. Clin Cancer Res.
10:5391–5402. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mozaffari F, Hansson L, Kiaii S, et al:
Signalling molecules and cytokine production in T cells of multiple
myeloma-increased abnormalities with advancing stage. Br J
Haematol. 124:315–324. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Herrmann R, Bodoky G, Ruhstaller T, et al:
Gemcitabine plus capecitabine compared with gemcitabine alone in
advanced pancreatic cancer: a randomized, multicenter, phase III
trial of the Swiss Group for Clinical Cancer Research and the
Central European Cooperative Oncology Group. J Clin Oncol.
25:2212–2217. 2007. View Article : Google Scholar
|
|
18
|
Clay TM, Hobeika AC, Mosca PJ, Lyerly HK
and Morse MA: Assays for monitoring cellular immune responses to
active immunotherapy of cancer. Clin Cancer Res. 7:1127–1135.
2001.PubMed/NCBI
|
|
19
|
Abdalla AO, Hansson L, Eriksson I, et al:
Idiotype protein vaccination in combination with adjuvant cytokines
in patients with multiple myeloma - evaluation of T-cell responses
by different read-out systems. Haematologica. 92:110–114. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vetsika EK, Konsolakis G, Aggouraki D, et
al: Immunological responses in cancer patients after vaccination
with the therapeutic telomerase-specific vaccine Vx-001. Cancer
Immunology Immunother. 61:157–168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gunturu KS, Rossi GR and Saif MW:
Immunotherapy updates in pancreatic cancer: are we there yet? Ther
Adv Med Oncol. 5:81–89. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu MH, Liao ZL, Zhao XY, et al:
hTERT-based therapy: a universal anticancer approach (Review).
Oncol Rep. 28:1945–1952. 2012.PubMed/NCBI
|
|
23
|
Seliger B: Molecular mechanisms of MHC
class I abnormalities and APM components in human tumors. Cancer
Immunol Immunother. 57:1719–1726. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kuttruff S: Immune responses and
association with clinical outcome of advanced colorectal cancer
patients treated with the multi-peptide vaccine IMA910. J Clin
Oncol. 30(Suppl): abs 147. 2012.
|
|
25
|
Faries MB, Hsueh EC, Ye X, Hoban M and
Morton DL: Effect of granulocyte/macrophage colony-stimulating
factor on vaccination with an allogeneic whole-cell melanoma
vaccine. Clin Cancer Res. 15:7029–7035. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Slingluff CL Jr, Petroni GR, Olson WC, et
al: Effect of granulocyte/macrophage colony-stimulating factor on
circulating CD8+ and CD4+ T-cell responses to
a multipeptide melanoma vaccine: outcome of a multicenter
randomized trial. Clin Cancer Res. 15:7036–7044. 2009.PubMed/NCBI
|
|
27
|
Ullenhag GJ, Frodin JE, Jeddi-Tehrani M,
et al: Durable carcinoembryonic antigen (CEA)-specific humoral and
cellular immune responses in colorectal carcinoma patients
vaccinated with recombinant CEA and granulocyte/macrophage
colony-stimulating factor. Clin Cancer Res. 10:3273–3281. 2004.
View Article : Google Scholar
|
|
28
|
Ullenhag GJ, Frodin JE, Strigard K,
Mellstedt H and Magnusson CG: Induction of IgG subclass responses
in colorectal carcinoma patients vaccinated with recombinant
carcinoembryonic antigen. Cancer Res. 62:1364–1369. 2002.
|
|
29
|
Staff C, Magnusson CG, Hojjat-Farsangi M,
et al: Induction of IgM, IgA and IgE antibodies in colorectal
cancer patients vaccinated with a recombinant CEA protein. J Clin
Immunol. 32:855–865. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kwak LW, Young HA, Pennington RW and Weeks
SD: Vaccination with syngeneic, lymphoma-derived immunoglobulin
idiotype combined with granulocyte/macrophage colony-stimulating
factor primes mice for a protective T-cell response. Proc Natl Acad
Sci USA. 93:10972–10977. 1996. View Article : Google Scholar
|
|
31
|
Parmiani G, Castelli C, Pilla L, Santinami
M, Colombo MP and Rivoltini L: Opposite immune functions of GM-CSF
administered as vaccine adjuvant in cancer patients. Ann Oncol.
18:226–232. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dillman RO, Wiemann M, Nayak SK, DeLeon C,
Hood K and DePriest C: Interferon-gamma or granulocyte-macrophage
colony-stimulating factor administered as adjuvants with a vaccine
of irradiated autologous tumor cells from short-term cell line
cultures: a randomized phase 2 trial of the cancer biotherapy
research group. J Immunother. 26:367–373. 2003. View Article : Google Scholar
|
|
33
|
Marshall JL, Gulley JL, Arlen PM, et al:
Phase I study of sequential vaccinations with
fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage
colony-stimulating factor, in patients with carcinoembryonic
antigen-expressing carcinomas. J Clin Oncol. 23:720–731. 2005.
View Article : Google Scholar
|
|
34
|
Ramanathan RK, Potter DM, Belani CP, et
al: Randomized trial of influenza vaccine with
granulocyte-macrophage colony-stimulating factor or placebo in
cancer patients. J Clin Oncol. 20:4313–4318. 2002. View Article : Google Scholar
|
|
35
|
Vergati M, Schlom J and Tsang KY: The
consequence of immune suppressive cells in the use of therapeutic
cancer vaccines and their importance in immune monitoring. J Biomed
Biotechnol. 2011:1824132011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Emens LA and Jaffee EM: Leveraging the
activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res.
65:8059–8064. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang G, Sun Y, Ji C, et al: Correlation
between the CD4+CD25high regulatory T cells and the
outcome of chemotherapy in advanced esophageal carcinoma.
Hepatogastroenterology. 60:704–708. 2013.
|
|
38
|
Hou JM, Liu JY, Yang L, et al: Combination
of low-dose gemcitabine and recombinant quail vascular endothelial
growth factor receptor-2 as a vaccine induces synergistic antitumor
activities. Oncology. 69:81–87. 2005. View Article : Google Scholar
|
|
39
|
Salazar LG GV, O’Meara M, et al:
Persistent immunity and survival after immunization with a Her2/neu
vaccine. J Clin Oncol. 27(Suppl): abs 15. 2009.
|
|
40
|
Middleton GW, Valle JW, Wadsley J, et al:
A phase III randomized trial of chemoimmunotherapy comprising
gemcitabine and capecitabine with or without telomerase vaccine
GV1001 in patients with locally advanced or metastatic pancreatic
cancer. J Clin Oncol. 31(Suppl): abs LBA4004. 2013.
|
|
41
|
Kokhaei P, Palma M, Hansson L, Osterborg
A, Mellstedt H and Choudhury A: Telomerase (hTERT 611–626) serves
as a tumor antigen in B-cell chronic lymphocytic leukemia and
generates spontaneously antileukemic, cytotoxic T cells. Exp
Hematol. 35:297–304. 2007.
|
|
42
|
Hodi FS, O’Day SJ, McDermott DF, et al:
Improved survival with ipilimumab in patients with metastatic
melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar
|
|
43
|
Topalian SL, Weiner GJ and Pardoll DM:
Cancer immunotherapy comes of age. J Clin Oncol. 29:4828–4836.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hale DF, Clifton GT, Sears AK, et al:
Cancer vaccines: should we be targeting patients with less
aggressive disease? Expert Rev Vaccines. 11:721–731. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bauer C, Sterzik A, Bauernfeind F, et al:
Concomitant gemcitabine therapy negatively affects DC
vaccine-induced CD8(+) T-cell and B-cell responses but improves
clinical efficacy in a murine pancreatic carcinoma model. Cancer
Immunol Immunother. 63:321–333. 2014. View Article : Google Scholar
|
